BACKGROUND: Vitiligo is a common skin disease characterized by autoimmune melanocyte destruction. Recent genetic studies suggest a lower susceptibility to melanoma in patients with vitiligo; however, lifetime melanoma prevalence in patients with vitiligo has not previously been studied. Nonmelanoma skin cancer (NMSC) prevalence has been studied, but only in small studies and with contradictory results. OBJECTIVES: This retrospective, comparative cohort survey was designed to assess lifetime prevalences of melanoma and NMSC in patients with vitiligo compared with nonvitiligo controls. METHODS: Patients with nonsegmental vitiligo, who visited our clinic between January 1995 and September 2010, and were aged 50 years or older at the time of the study, were invited to participate in a postal survey. The questions regarded demographics, vitiligo characteristics, phototherapy history, skin cancer risk factors and the number of skin cancers experienced during the patient's lifetime. Patients were asked to have their partner fill in a control questionnaire. All skin cancers were validated by a pathology report. In total 2635 invitations were sent and 1307 eligible questionnaires were returned (50%). Multivariate logistic regression models were used to quantify adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between vitiligo and lifetime prevalences of melanoma and NMSC. RESULTS: Adjusted for confounders, patients with vitiligo had a threefold lower probability of developing melanoma (adjusted OR 0·32; 95% CI 0·12-0·88) and NMSC (adjusted OR 0·28; 95% CI 0·16-0·50). Subgroup analyses of patients treated with narrowband ultraviolet (UV) B, and psoralen and UVA did not show dose-related trends of increased age-adjusted lifetime prevalence of melanoma or NMSC. CONCLUSIONS: Our findings suggest that patients with vitiligo have a decreased risk of both melanoma and NMSC.
BACKGROUND: Vitiligo is a common skin disease characterized by autoimmune melanocyte destruction. Recent genetic studies suggest a lower susceptibility to melanoma in patients with vitiligo; however, lifetime melanoma prevalence in patients with vitiligo has not previously been studied. Nonmelanoma skin cancer (NMSC) prevalence has been studied, but only in small studies and with contradictory results. OBJECTIVES: This retrospective, comparative cohort survey was designed to assess lifetime prevalences of melanoma and NMSC in patients with vitiligo compared with nonvitiligo controls. METHODS:Patients with nonsegmental vitiligo, who visited our clinic between January 1995 and September 2010, and were aged 50 years or older at the time of the study, were invited to participate in a postal survey. The questions regarded demographics, vitiligo characteristics, phototherapy history, skin cancer risk factors and the number of skin cancers experienced during the patient's lifetime. Patients were asked to have their partner fill in a control questionnaire. All skin cancers were validated by a pathology report. In total 2635 invitations were sent and 1307 eligible questionnaires were returned (50%). Multivariate logistic regression models were used to quantify adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between vitiligo and lifetime prevalences of melanoma and NMSC. RESULTS: Adjusted for confounders, patients with vitiligo had a threefold lower probability of developing melanoma (adjusted OR 0·32; 95% CI 0·12-0·88) and NMSC (adjusted OR 0·28; 95% CI 0·16-0·50). Subgroup analyses of patients treated with narrowband ultraviolet (UV) B, and psoralen and UVA did not show dose-related trends of increased age-adjusted lifetime prevalence of melanoma or NMSC. CONCLUSIONS: Our findings suggest that patients with vitiligo have a decreased risk of both melanoma and NMSC.
Authors: Sérgio Schalka; Denise Steiner; Flávia Naranjo Ravelli; Tatiana Steiner; Aripuanã Cobério Terena; Carolina Reato Marçon; Eloisa Leis Ayres; Flávia Alvim Sant'anna Addor; Helio Amante Miot; Humberto Ponzio; Ida Duarte; Jane Neffá; José Antônio Jabur da Cunha; Juliana Catucci Boza; Luciana de Paula Samorano; Marcelo de Paula Corrêa; Marcus Maia; Nilton Nasser; Olga Maria Rodrigues Ribeiro Leite; Otávio Sergio Lopes; Pedro Dantas Oliveira; Renata Leal Bregunci Meyer; Tânia Cestari; Vitor Manoel Silva dos Reis; Vitória Regina Pedreira de Almeida Rego Journal: An Bras Dermatol Date: 2014 Nov-Dec Impact factor: 1.896
Authors: Xiaozheng Kang; Hongliang Liu; Mark W Onaitis; Zhensheng Liu; Kouros Owzar; Younghun Han; Li Su; Yongyue Wei; Rayjean J Hung; Yonathan Brhane; John McLaughlin; Paul Brennan; Heike Bickeböller; Albert Rosenberger; Richard S Houlston; Neil Caporaso; Maria Teresa Landi; Joachim Heinrich; Angela Risch; Xifeng Wu; Yuanqing Ye; David C Christiani; Christopher I Amos; Qingyi Wei Journal: Carcinogenesis Date: 2016-02-10 Impact factor: 4.944